drugset
drugset / Trial / NCT02969876

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

NCT02969876 ↗

Phase 4 Terminated 2 enrolled Massachusetts General Hospital Takeda · collab
NaSingle-groupOpen-labelBasic science

Summary

The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.

Timeline

Start
2017-08-24
Primary completion
2018-08-06
Completion
2018-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown — —

Indications

major depressive disorder